Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $8.5400 (-3.94%) ($8.4000 - $8.9600) on Tue. Oct. 6, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.52% (three month average) | RSI | 34 | Latest Price | $8.5400(-3.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -5.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) ARKK(33%) XBI(33%) BLOK(31%) IBB(30%) | Factors Impacting HTBX price | HTBX will decline at least -5.76% in a week (0% probabilities). VXX(-19%) VIXM(-18%) UUP(-14%) XLU(-4%) IGOV(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -5.76% (StdDev 11.52%) | Hourly BBV | 0.2 () | Intraday Trend | -3.2% | | | |
|
Resistance Level | $8.78 | 5 Day Moving Average | $8.64(-1.16%) | 10 Day Moving Average | $8.7(-1.84%) | 20 Day Moving Average | $8.78(-2.73%) | To recent high | -66.3% | To recent low | 44.4% | Market Cap | $940m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |